Effects of estetrol/drospirenone versus ethinyl estradiol/drospirenone on glucose tolerance in women with polycystic ovary syndrome: A randomised controlled trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70126 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Phattarika Bunyapipat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Ethinyl Estradiol, Androstenes, Estetrol. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Aims
To compare the effects of estetrol/drospirenone ( E4 / DRSP ) and ethinyl estradiol/drospirenone ( EE / DRSP ) on glucose tolerance in women with polycystic ovary syndrome ( PCOS ). Materials and Methods This open‐label, randomised crossover trial was conducted from January 2024 to January 2025. Women with PCOS , diagnosed according to the modified 2003 Rotterdam criteria, received three cycles of either E4 15 mg/ DRSP 3 mg or EE 30 mcg/ DRSP 3 mg. After a 2‐month washout, participants crossed over to the alternate regimen for three further cycles. Glucose tolerance (via 75 g oral glucose tolerance test [ OGTT ]), insulin levels and homeostatic model assessment for insulin resistance ( HOMA ‐ IR ) were compared between treatments.
Results
Of 66 women enrolled, 61 completed both treatment phases. Baseline characteristics were comparable. No significant differences were observed in the mean changes in 2‐h OGTT ( E4 / DRSP : 4.65 mg/ dL [95% confidence interval ( CI ) −2.37 to 11.66] vs. EE / DRSP : 14.40 mg/ dL [95% CI 7.50–21.29]; p = 0.05; upper boundary for non‐inferiority margin of 14.29), 1‐h insulin levels (−1.04 μU / mL [95% CI −25.94 to 23.86] vs. −0.77 μU / mL [95% CI −25.24 to 23.70]; p = 0.99; upper boundary for non‐inferiority margin of 50.72) or HOMA ‐ IR (0.28 [95% CI −0.24 to 0.80] vs. 0.60 [95% CI 0.09–1.11]; p = 0.39; upper boundary for non‐inferiority margin of 1.06).
Conclusion
E4/DRSP was not inferior to EE/DRSP in its effects on glucose tolerance, insulin levels and HOMA‐IR, supporting its use as a potential oral contraceptive option in women with PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
ORCID-Profile: Satit Klangsin, Krantarat Peeyananjarassri, Saranya Wattanakumtornkul, Alan Geater
Zitieren
APA
Bunyapipat, P., Klangsin, S., Peeyananjarassri, K., Wattanakumtornkul, S., Katesuwan, S., Geater, A., & Numit, A. (2025). Effects of estetrol/drospirenone versus ethinyl estradiol/drospirenone on glucose tolerance in women with polycystic ovary syndrome: A randomised controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70126
Vancouver
Bunyapipat P, Klangsin S, Peeyananjarassri K, Wattanakumtornkul S, Katesuwan S, Geater A, et al. Effects of estetrol/drospirenone versus ethinyl estradiol/drospirenone on glucose tolerance in women with polycystic ovary syndrome: A randomised controlled trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70126
BibTeX
@article{Bunyapipat2025,
author = {Bunyapipat, Phattarika and Klangsin, Satit and Peeyananjarassri, Krantarat and Wattanakumtornkul, Saranya and Katesuwan, Sirapat and Geater, Alan and Numit, Amornkan},
title = {Effects of estetrol/drospirenone versus ethinyl estradiol/drospirenone on glucose tolerance in women with polycystic ovary syndrome: A randomised controlled trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70126}
}
EUVIMED